Insight Molecular Diagnostics I
5.91-0.31 (-4.98%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · IMDX · USD
Key Stats
Market Cap
169.14MP/E (TTM)
-Basic EPS (TTM)
-3.91Dividend Yield
0%Recent Filings
8-K
Executive salary increases approved
Insight Molecular Diagnostics boosted base salaries for its top executives effective September 15, 2025, lifting CEO Joshua Riggs from $420,000 to $520,000 and CFO Andrea James from $341,250 to $441,250. The Board and Compensation Committee approved the raises on September 16, signaling confidence in leadership amid diagnostics market pressures. Executives earn more now. No further compensation details disclosed.
8-K
Q2 revenue surges; FDA progress
Insight Molecular Diagnostics reported Q2 2025 revenue of $518,000, up sharply from $104,000 a year earlier, driven by laboratory services and the first sale of GraftAssureIQ research-use-only kits to a Swiss hospital. Gross margin expanded to 67.6% on lab efficiencies, yet net loss widened to $9.7 million amid R&D investments for the FDA-bound GraftAssureDx. Progress includes a productive FDA meeting and top-tier trial sites like Mayo Clinic. Cash burn hit $6.3 million, leaving $26.0 million on hand. Regulatory approval remains key to unlocking the $1 billion transplant market.
10-Q
Q2 FY2025 results
Insight Molecular Diagnostics posted Q2 revenue of $518K, up 398% y/y from $104K, driven by lab services from one major client and first kitted product sales of $24K, while gross profit climbed to $350K from $50K. Operating loss widened to $9.8M from $4.6M, fueled by R&D ramp-up to $3.3M (up 34% y/y) for transplant and oncology tests, plus a $2.8M hit from contingent consideration fair value changes—net loss differs from operating by that amount due to valuation adjustments. Cash swelled to $24.3M after a $28.7M net raise in February, supporting liquidity amid $41.6M contingent liabilities tied to past acquisitions. Bio-Rad partnership advances RUO kits, with first sales in May. Yet regulatory hurdles for IVD approvals loom large.
8-K
Annual meeting approves directors, auditors
Insight Molecular Diagnostics Inc. held its 2025 Annual Meeting on June 27, electing Joshua Riggs, Andrew Arno, Andrew J. Last, and Louis E. Silverman as directors until 2026. Shareholders ratified CBIZ CPAs P.C. as auditors for 2025, approved executive compensation for 2024 on an advisory basis, and authorized adding 1,500,000 shares to the 2018 Equity Incentive Plan, totaling 3,800,000. With 73.46% turnout, the votes signal strong governance alignment. This boosts equity incentive capacity for talent retention.
8-K
Name change to iMDx effective
Insight Molecular Diagnostics Inc., formerly Oncocyte Corp, completed its name change on June 13, 2025, via a California merger, with stock trading shifting to IMDX on Nasdaq starting June 18. The rebrand aligns operations with its pivot to transplant rejection testing, relocating headquarters to Nashville while retaining German R&D. This sharpens focus on commercializing dd-cfDNA kits in a $1 billion market. Rebranding unifies products under GraftAssure, but regulatory approvals remain uncertain.
BDSX
Biodesix, Inc.
6.54-0.01
CDNA
CareDx, Inc.
14.28-0.39
CODX
Co-Diagnostics, Inc.
0.49-0.08
DGX
Quest Diagnostics Incorporated
174.78-3.50
IDXG
Interpace Biosciences, Inc.
1.10-0.04
ILMN
Illumina, Inc.
95.03-2.77
ISPC
iSpecimen Inc.
0.80-0.06
MDXH
MDxHealth SA
4.81-0.19
MYGN
Myriad Genetics, Inc.
7.91-0.22
PSNL
Personalis, Inc.
9.55-0.20